INCY Overview

Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.

Wall Street analysts forecast INCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is100.31 USD with a low forecast of 73.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Incyte Corp revenue for the last quarter amounts to 1.27B USD, increased 20.87

Incyte Corp. EPS for the last quarter amounts to 1.47 USD, increased 83.75

Incyte Corp (INCY) has 2844 emplpoyees as of June 20 2026.

Today INCY has the market capitalization of 19.62B USD.